Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation

PHASE4CompletedINTERVENTIONAL
Enrollment

783

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

August 13, 2020

Study Completion Date

August 13, 2020

Conditions
Gastrointestinal InjuryIschemic Heart Disease
Interventions
DRUG

Aspirin + clopidogrel

After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.

DRUG

Clopidogrel monotherapy

After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.

DRUG

Aspirin monotherapy

After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.

Trial Locations (1)

110016

General Hospital of Shenyang Military Region, Shenyang

All Listed Sponsors
collaborator

Changhai Hospital

OTHER

collaborator

ANKON medical technologies (Shanghai)Co.,LTD

UNKNOWN

lead

Shenyang Northern Hospital

OTHER

NCT03198741 - Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation | Biotech Hunter | Biotech Hunter